E2F-high cancers | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

111,101 results for “E2F-high cancers”

Trials

View all 88593 →

Amatuximab for High Mesothelin Cancers

7 participants · First posted Aug 10, 2011

A Vaccine Study for High Risk Cancers

First posted Jul 23, 2009

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

18 participants · First posted Oct 31, 2017

Drugs

View all 1910 →

Werner inhibitor (MSI-high cancers/sensitive cancers)

High Titer IVIG

high-cannabidiol botanical formulation

Organizations

View all 565 →

CIBC CANADIAN HIGH DIVIDEND COVERED CANADIAN HIGH DIVIDEND COVERED CALL ETF

India

HIGH POINT UNIVERSITY

United States

High Desert Respiratory

United States

News

View all 20033 →

Circle Pharma to Reveal Dual Mechanism of Novel Cyclin A/B RxL Inhibitors at AACR 2025

Circle Pharma's Novel Cyclin Inhibitor Shows Promise Against E2F-Driven Cancers in Nature Study

Dana-Farber Researchers Launch Phase 1 Trial of Novel Cyclin Inhibitor for Small Cell Lung Cancer

Page 1 of 11111